Disclosed is a pharmaceutical composition for treating migraine in a mammal, including a human, which comprises a 5HT1, receptor agonist in combination with caffeine and a cyclooxygenase-2 (COX-2) inhibitor. Examples of the 5HT1 receptor agonist are eletriptan, rizatriptan, naratriptan, sumatriptan, zolmitriptan and ergotamine.
COMBINATION THERAPY FOR THE TREATMENT OF MIGRAINE